United Health Products Q2 net loss narrows to $284,140; revenue flat with no revenue
UEEC•FDA-related work remains in focus
FDA path remains in focus: NAMSA was selected July 6, 2026 to sponsor a planned IDE study for CelluSTAT as PMA work continues.
Quarterly loss narrows as revenue remains nil
United Health Products posted a net loss of $284,140 for the quarter ended June 30, 2026, narrowing from $315,187 a year earlier.
Operating loss improved to $166,850 from $268,356; revenue was flat with no revenue in both periods.
Other expense widens on higher interest and derivative loss
Other expense widened to $117,290 from $46,831, on higher interest expense and a larger loss on derivative liabilities.
